References
- Apostolidis SA, Crispin JC, Tsokos GC. IL-17-producing T cells in lupus nephritis. Lupus 2011;20:120–4.
- Wong CK, Ho CY, Li EK, Lam CW. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000;9:589–93.
- Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991;9:243–69.
- Dolff S, Quandt D, Wilde B, Feldkamp T, Hua F, Cai X, . Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus. Arthritis Res Ther 2010;12:R150.
- Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, . BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001;293:2108–11.
- Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, . Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008;58:2453–9.
- Zhang J, Roschke V, Baker KP, Wang Z, Alarcón GS, Fessler BJ, . Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001;166:6–10.
- Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, . A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918–30.
- Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, . Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721–31.
- Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, . Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009;10:778–85.
- A randomized, placebo-controlled, double-blind study to evaluate the efficacy, safety, tolerability, and pharmacodynamics of belimumab in subjects with generalized myasthenia gravis (MG). 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01480596.